Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 28, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:00 ET
|
Cabaletta Bio
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical...
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
June 14, 2024 02:00 ET
|
Cabaletta Bio
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell...
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 07:00 ET
|
Cabaletta Bio
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial clinical...
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024 07:00 ET
|
Cabaletta Bio
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™...
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...